Işılay Kalan Sari

Işılay Kalan Sari

Auto-generated profile, based on publicly available information

Işılay Kalan Sari

Department of Endocrinology and Metabolism, Antalya Training and Research Hospital, University of Health Sciences, Antalya, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
ISIşılay Kalan Sarı
Işılay Kalan Sarı
OKOlgun Keskin
Olgun Keskin
AKAyşegül Seremet Keskin
Ayşegül Seremet Keskin
HEHamit Yaşar Elli̇dağ
Hamit Yaşar Elli̇dağ
OHOrbay Harmandar
Orbay Harmandar
Background/Aim. Coronavirus disease 2019 (COVID-19) is a life-threatening disease characterized by a prothrombotic state. Because homocysteine (Hcy) is a potential biomarker in thrombotic disease, this article aims to highlight the role of Hcy in the prognosis of COVID-19 pneumonia. Methods. This prospective study was conducted between April 2021 and December 2021 at the University of Health Sciences, Antalya Training and Research Hospital. 162 patients admitted to the emergency department for COVID-19 pneumonia and scheduled for hospitalization in the intensive care unit (ICU) or COVID-19 ward of the chest disease department were included in the study. Hcy levels and other necessary laboratory parameters were analyzed. Results. 134 patients were admitted to the COVID-19 ward and 28 to the ICU. Hcy levels were significantly higher in ICU patients than in ward patients ( p : 0.001 ). Of the 134 patients, 55 later required ICU treatment for various reasons and were transferred to the ICU. Hcy ( p : 0.010 ), ferritin ( p : 0.041 ), and LDH ( p : 0.010 ) were significantly higher in patients who were transferred to the ICU than in patients who remained in the ward. The Hcy level was associated with a poor prognosis. It was found that each unit increase in the Hcy level approximately doubled the risk of death in patients with COVID-19 (odds ratio: 1.753). Discussion. There are few studies examining the association between high Hcy levels and disease severity in COVID-19. Our study supports previous studies and shows the association between the need for intensive care and high Hcy levels. Conclusion. A high Hcy value is a helpful marker in determining the need for critical care on admission to the emergency department and a marker of poor prognosis in COVID-19 pneumonia.

30 May 2022 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
ISIşılay Kalan Sari
Işılay Kalan Sari
SCSerkan Ceylan
Serkan Ceylan
Introduction: Obesity is a growing health problem. Many drugs have been developed to treat obesity. Orlistat is a widely used drug to treat this disease. Metformin is an antidiabetic drug. Clinicians often prescribe it to treat insulin resistance and achieve weight loss. Our research aims to compare the effects of orlistat alone and its combination with metformin on weight loss and insulin resistance. Material and Method: This retrospective study was conducted by scanning the data of patients who presented to Antalya Training and Research Hospital Endocrinology, and General Surgery Clinics between 2016 and 2021. 42 morbidly obese patients who met inclusion and exclusion criteria and were prescribed orlistat plus metformin (group 1, n: 28) or orlistat alone (group 2, n: 14) along with a low-calorie diet for three months and were taking it regularly were included. Subsequently, weight, body mass index, fasting blood glucose, fasting insulin, and HOMA-IR (homeostasis model assessment for insulin resistance) were recorded and analyzed at baseline and after three months of taking the medications. Results: After 3 months of treatment, significant weight loss was achieved in both groups compared to baseline weight (p=0.001 group 1, p=0.003 group 2). HOMA-IR values decreased significantly in both groups (p=0.001 group 1, p=0.01 group 2). Both groups lost the same amount of weight after three months (p=0.06). Conclusion: In morbidly obese patients without prediabetes or diabetes, the addition of metformin to orlistat therapy did not add benefits in terms of weight loss or insulin resistance.

25 September 2022 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
ISIşılay Kalan Sari
Işılay Kalan Sari
MCMuhammed Ali Coşkuner
Muhammed Ali Coşkuner
Aim: Vitamin D (vitD) is primarily responsible for bone formation and mineralization. However, in recent years, it has been suggested that vitD may play a role as an immune modulator in the development of numerous diseases, including autoimmune diseases. It has been observed that there is an association between chronic autoimmune thyroiditis (AIT) and vitD levels. This study aims to investigate whether there are differences in the levels of 25-hydroxy vitamin D [25(OH)D], calcium, and phosphorus in patients with subclinical hypothyroidism (SCH) due to AIT, in patients with antibody-negative subclinical hypothyroidism (ANSCH), and in healthy control subjects. Material and Method: Data from 50 newly diagnosed patients with SCH (35 of whom AIT) and 50 euthyroid and antibody-negative healthy controls who presented to the Department of Endocrinology and Internal Medicine at our hospital between 2018 and 2020 were retrospectively reviewed. Calcium, phosphorus, and 25(OH)D levels of patients and controls were compared. Results: Serum 25(OH)D levels were significantly lower in patients compared to controls (16.2±7.8 ng/ml and 20.4±8.2 ng/ml, respectively; p=0.024). Serum levels of calcium (p=0.081) and phosphorus (p=0.712) did not differ between groups. In a subgroup analysis, patients with AIT had significantly lower 25(OH)D values than controls (p=0.009). Compared to controls, 25(OH)D levels were comparable in the ANSCH group (p=0.096). 25(OH)D level was higher in the AIT group than in the ANSCH group (p=0.01). Conclusion: Our results show that patients with SCH have lower 25(OH)D levels than healthy controls. However, this difference is significant in patients with AIT. It is recommended to screen for vitD deficiency in patients with SCH due to AIT.

15 March 2024 in Experimental Biomedical Research
Verified
Journal Article
Open access
PDF file
ISIşılay Kalan Sari
Işılay Kalan Sari
FBFeyzi Bostan
Feyzi Bostan
CÇCeren Çevik
Ceren Çevik
Aim: To investigate the effects of short-term oral intake of spironolactone on parathyroid hormone (PTH) and calcium levels, as well as other biochemical and clinical parameters in normotensive female patients with polycystic ovary syndrome (PCOS). Method: 32 PCOS patients were studied at baseline and three months after regular intake of a daily dose of 50 mg or 100 mg spironolactone. PTH, calcium and other biochemical tests as well as clinical parameters were evaluated at baseline and after three months. Results: Body mass index and serum PTH levels decreased significantly after treatment (p: 0.021 and p: 0.043, respectively). Mean high-density lipoprotein was significantly decreased after treatment (p: 0.011). No significant change was observed in calcium, phosphorus, total cholesterol, triglycerides, and fasting blood glucose levels. Serum testosterone and dehydroepiandrosterone sulphate decreased significantly after 3 months of therapy (p: 0.000 and p: 0.006; respectively). Conclusions: In our study, taking spironolactone at a dose of 100 mg/day lowered PTH levels and had a positive effect on weight loss and insulin resistance. New studies are needed to investigate the effects of treatment with spironolactone on bone and metabolism. It is recommended to monitor dyslipidemia while taking the drug.

4 February 2026 in Journal of Investigative Medicine
Verified
Journal Article
Closed access
ISIşılay Kalan Sarı
Işılay Kalan Sarı
OKOlgun Keskin
Olgun Keskin
AKAyşegül Seremet Keskin
Ayşegül Seremet Keskin
Respiratory tract infections, which are among the most common infections, can be serious and fatal in patients with diabetes mellitus (DM). Studies show that community-acquired pneumonia (CAP) is more severe in people with DM. However, the impact of serum glucose and HbA1c levels on mortality associated with pneumonia remains controversial. We designed this study to investigate the impact of DM on the prognosis of pneumonia and to elucidate the relationship between glycaemic parameters and mortality in CAP. The study included a retrospective analysis of patients with CAP treated in the Chest Diseases Department and Intensive Care Unit (ICU) of Antalya Research and Training Hospital between January 2022 and June 2025. Patient demographics, clinical and laboratory parameters and clinical outcomes were analysed. The mortality rate of patients with DM was significantly higher than that of patients without DM ( p = 0.028). When comparing discharged and deceased patients with DM, HbA1c and random blood glucose on admission were higher in the deceased patients ( p = 0.012 and 0.019, respectively). Regression analysis identified C-reactive protein ( p = 0.024), length of ICU stay ( p = 0.005), HbA1c ( p = 0.032), and Pneumonia Severity Index score ( p = 0.008) as significant predictors of mortality. DM is not only a comorbidity but also a factor that strongly influences the clinical course of CAP. Our study confirms the finding that patients with DM have a poor prognosis and high mortality during the course of CAP. It also showed that HbA1c and blood glucose levels at admission are associated with mortality. As pneumonia may be more severe in patients with high blood glucose and HbA1c on admission, it should be considered that these patients with DM may need to be treated earlier in the ICU.

1 January 2025 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
ISIşılay Kalan Sarı
Işılay Kalan Sarı
MAMehmet Aksoy
Mehmet Aksoy
Several studies suggest an increased prevalence of obesity among patients with primary hyperparathyroidism (PHPT). Proposed mechanisms include parathyroid hormone (PTH) resistance, resistance to adipokines, and reduced lipolysis. Obesity may influence the clinical severity and presentation of PHPT. In addition to obesity, metabolic disorders such as diabetes mellitus and hypertension are also frequently observed in PHPT; however, the specific contribution of obesity to these comorbidities remains unclear. This study aimed to determine the prevalence of obesity in PHPT and to investigate its association with clinical presentation, laboratory parameters, and comorbid conditions. We retrospectively analyzed data from 152 patients with surgically confirmed PHPT. Patient records were reviewed for body mass index (BMI), laboratory values, coexisting metabolic conditions, and PHPT‐related complications such as nephrolithiasis, osteoporosis, and fracture history. Among the patients, 20.4% had prediabetes, 13.8% had diabetes, and 34.9% had hypertension. Obesity (BMI ≥ 30 kg/m 2 ) was present in 27%, and 36.8% were overweight. Thyroid nodules were found in 50.7%, and anti–thyroid peroxidase (anti‐TPO) positivity was detected in 16.4%. Serum calcium and PTH levels were significantly higher in obese patients compared to those with normal BMI ( p ≤ 0.001 and p = 0.017, respectively). There was no significant difference in the incidence of fractures, osteoporosis, or nephrolithiasis between the obese and nonobese groups. While diabetes was more prevalent in the nonobese group overall, subgroup analysis revealed a higher frequency of diabetes in overweight and obese patients compared to those with normal BMI. The prevalence of obesity in PHPT was higher than that in the general population. Although obesity was not associated with an increased frequency of osteoporosis, nephrolithiasis, or fractures, elevated serum calcium and PTH levels in obese patients may suggest a relationship with disease severity.